Sahajanand Medical Technologies

What Sahajanand Medical Technologies does

Sahajanand Medical Technologies (SMT) is a Surat-headquartered Indian medical device company that develops and manufactures minimally invasive cardiovascular devices, serving cardiologists, interventional specialists, hospitals, and catheterization laboratories worldwide. The company's product portfolio spans three categories: coronary intervention devices (drug-eluting stents including Supraflex Cruz with 60 μm ultra-thin struts and biodegradable polymer coating, Supraflex, Tetriflex, Tetrilimus, Everoflex, and PTCA balloon catheters Wilma and Pipit), structural heart devices (Hydra self-expanding TAVI system and Cocoon occluders for septal, PFO, duct, and VSD defects), and peripheral intervention devices (Renofit renal/biliary stent and Peripherics drug-coated PTA balloon). Supporting accessories include the SMT i30 inflation device, Identity aspiration catheter, and Easy-Catch+ Y connector.

SMT operates two ISO 50001:2018-certified manufacturing facilities in Surat and Hyderabad, India, and maintains an R&D centre in Galway, Ireland, established in 2016. The company pioneered biodegradable polymer coating technology for coronary stents and developed proprietary platinum nanocoating for occluders. Its clinical evidence base includes the TALENT randomized trial demonstrating a 61% reduction in clinically driven TLR, published in The Lancet in 2019. Products are CE marked and distributed across 75+ countries through wholly-owned subsidiaries in Ireland, Switzerland, France, Germany, Spain, the USA, Brazil, and Australia, combined with regional distributor networks.

SMT generates revenue through B2B hardware sales of cardiovascular devices to healthcare institutions, primarily via direct enterprise field sales. The company is privately held, with institutional investors including Morgan Stanley Private Equity Asia, Samara Capital, and Kotak Mahindra, and received SEBI approval for its IPO in November 2025. Strategic acquisitions of Vascular Concepts and Vascular Innovations (Thailand) in 2020 expanded the company into structural heart, while a 2022 partnership with Penumbra further broadened its cardiovascular portfolio.

Name

Sahajanand Medical Technologies

Legal name

Sahajanand Medical Technologies Limited

Website

https://smtpl.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Sahajanand Medical Technologies is an India-based medical device company that develops and manufactures minimally invasive cardiovascular devices, including coronary drug-eluting stents, PTCA balloons, TAVI systems, and occluders, serving hospitals and interventional cardiologists across 75+ countries.

Ownership category

akta.pro rank

Product category

Cardiovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

akta.pro secondary industries

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB), Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)

Keywords

• Coronary stents
• Cardiovascular medical devices
• Structural heart devices
• PTCA balloon catheters
• Closure occluders

Headquarters

HQ city

Surat

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Cardiovascular Medical Devices: SMT generates revenue through the sale of minimally invasive cardiovascular devices including coronary stents, PTCA balloon catheters, structural heart devices, and closure occluders

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Sahajanand Medical Technologies is a developer and manufacturer of minimally invasive cardiovascular medical devices, including drug-eluting coronary stents (Supraflex Cruz, Supraflex, Tetriflex, Tetrilimus), PTCA balloon catheters (Wilma, Pipit), structural heart devices (Hydra TAVI system), and closure occluders (Cocoon family for Septal, PFO, Duct, and VSD defects), as well as peripheral intervention devices (Renofit renal/biliary stent, Peripherics drug-coated PTA balloon). The company manufactures at facilities in Surat and Hyderabad, India, and sells its devices to hospitals, cath labs, and interventional cardiologists across 75+ countries.

Product overview

Sahajanand Medical Technologies (SMT) is a global medical device company developing and manufacturing minimally invasive cardiovascular devices. The product portfolio encompasses three main categories: (1) Coronary Intervention devices including drug-eluting stents (Supraflex Cruz, Supraflex, Tetriflex, Tetrilimus, Everoflex) and PTCA balloon catheters (Wilma NC/SC, Pipit NC/SC); (2) Structural Heart Devices including the Hydra TAVI system and Cocoon occluder family (Septal, PFO, Duct, and VSD occluders) for congenital heart defect treatment; and (3) Peripheral Intervention Devices including the Renofit renal/biliary stent and Peripherics drug-coated balloon. SMT also offers supporting accessories including inflation devices, aspiration catheters, and Y-connectors. The company pioneered biodegradable polymer coating technology in coronary stents and has developed proprietary platinum nanocoating for occluder devices.

Differentiator

Problem solved

Functional benefit

Brands

• Supraflex Cruz: Sirolimus Eluting Cobalt Chromium Coronary Stent System providing ultimate deliverability for complex PCI cases
• Pipit
• Wilma
• Peripherics
• Tetriflex
• Tetrilimus
• Renofit
• Hydra
• Cocoon
• Supralimus
• Infinnium
• Everoflex

Products and services

• Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System with ultra-thin 60 μm struts and biodegradable polymer coating, designed for ultimate deliverability in complex PCI cases including tortuous vessels and bifurcations.
• Supraflex Sirolimus eluting coronary stent system with ultrathin struts and biodegradable polymer coating for treatment of coronary artery disease.
• Tetriflex Sirolimus Eluting Cobalt Chromium Coronary Stent System with thin-strut design for coronary interventions.
• Tetrilimus Everolimus Eluting Cobalt Chromium Coronary Stent System with biodegradable polymer for drug-eluting stent applications.
• Supraflex Star Sirolimus eluting coronary stent system variant in the Supraflex family.
• Flexinnium Coronary stent system in SMT portfolio.
• Everoflex Everolimus eluting coronary stent system with biodegradable polymer coating.
• Pipit NC Non-compliant PTCA balloon dilatation catheter with 6F KBT compatibility, featuring lowest tip profile and multi-layered polyamide balloon material for post-stent dilatation.
• Pipit SC Semi-compliant PTCA balloon catheter with lowest peak track force, 6F KBT compatibility, advanced multi-layered balloon material, and selective hydrophilic coating for enhanced crossability.
• Wilma NC Non-compliant balloon catheter with ultra-low tip entry profile (0.41 mm), 20 atm rated burst pressure, and excellent deflation time for high-pressure dilatation.
• Wilma SC Semi-compliant PTCA dilatation catheter for coronary balloon angioplasty procedures.
• Hydra Aortic Valve (Hydra THV) Self-expanding TAVI (Transcatheter Aortic Valve Implantation) device made from bovine pericardium with supra-annular valve position, recapturable design, and proprietary anti-calcification treatment. Available in 22mm, 26mm, and 30mm sizes.
• Cocoon VSD Occluder Self-expanding double disc device for ventricular septal defect closure with platinum nanocoating technology, nitinol wire construction, and ability to recapture and redeploy. Available in 4, 7, and 10 mm waist lengths.
• Cocoon Duct Occluder Hat-shaped self-expanding nitinol device with platinum nanocoating for patent ductus arteriosus closure. Features retention skirt design and 100% occlusion rate at one-month follow-up.
• Cocoon Septal Occluder Transcatheter closure device for secundum atrial septal defect with platinum-coated nitinol wire construction.
• Cocoon PFO Occluder Transcatheter closure device for patent foramen ovale using Cocoon occluder technology for stroke prevention.
• Renofit Balloon Expandable Cobalt Chromium Renal and Biliary Stent System with 150 μm strut thickness, optimal scaffolding, high radial strength, and excellent deliverability. Features no foreshortening and reduced risk of strut fracture.
• Peripherics Paclitaxel Drug Coated PTA (Percutaneous Transluminal Angioplasty) Balloon Catheter with proprietary coating technology, 2 μg/mm² paclitaxel drug load, and uniform coating distribution. Available in OTW BTK and OTW SFA configurations.
• Infinnium Drug-eluting stent with biodegradable polymer coating (CE certified 2005).
• Supralimus Sirolimus-eluting coronary stent with biodegradable polymer coating.

Quantifiable outcome

• TALENT Trial: 61% reduction in clinically driven TLR in per-protocol analysis published in The Lancet
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• PenumbracoreStrategic or Co-development Partner · 1 January 2022SMT forged a strategic partnership with Penumbra in 2022, expanding its portfolio and market presence in the cardiovascular devices sector.
• Vascular Innovations Co., Ltd.coreOEM/ Whitelabel/ Licensing PartnerVascular Innovations Co., Ltd. Thailand is a subsidiary and SMT group company that manufactures Hydra TAVI device and Cocoon occluders.
• Vascular ConceptscoreStrategic or Co-development PartnerSMT announced entry in Structural Heart Segment through acquisition of Vascular Concepts in 2020, expanding its capabilities in structural heart devices.

Scale indicators4 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• Abbott Laboratories: Global medical device leader with the Xience family of DES, structural heart portfolio, and peripheral devices. Directly competes with SMT in coronary stents while offering a vastly broader cardiovascular portfolio.
• Boston Scientific: Major cardiovascular device company with the Synergy DES, ACURATE TAVI (post-Bolt acquisition), and peripheral intervention portfolio. SMT's CTO previously worked at Boston Scientific, indicating talent mobility in the space.
• Medtronic: World's largest medical device company with the Resolute Onyx DES, Evolut TAVI platform, and broad peripheral and structural heart offerings. Dominant in coronary stents alongside Abbott.
• Edwards Lifesciences: Global leader in structural heart with the SAPIEN TAVI platform. Competes with SMT's Hydra TAVI in transcatheter aortic valve replacement, though Edwards' portfolio is heavily concentrated in structural heart.
• B. Braun: German medical device and pharmaceutical company with a broad cardiovascular portfolio including coronary stents and interventional accessories. Operates as a broader incumbent across multiple device categories.

Direct peers

• Terumo: Japanese medical device company with the Ultimaster DES and other coronary stent systems. A direct competitor in drug-eluting stents with comparable technology positioning and global commercial presence.
• MicroPort Scientific: Hong Kong-listed cardiovascular medical device company with coronary stents (Firehawk), structural heart, and orthopedic businesses. Comparable emerging-market manufacturer with global commercial ambition.

Emerging players

• Lepu Medical: Chinese cardiovascular medical device company with coronary stents, occluders, and balloon products. Comparable emerging-economy DES manufacturer expanding globally, similar to SMT's positioning.
• Meril Life Sciences: Indian medical device company developing coronary stents (Myra), structural heart, and orthopedic products. Closest India-based peer to SMT with overlapping product portfolio and domestic manufacturing base.
• Venus Medtech: Chinese structural heart company focused on TAVI and TTVR devices. Direct competitor to SMT's Hydra in structural heart with comparable technology positioning and emerging-market origin.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/sahajanandmedi
• YouTubeyoutube.com/channel/UCPcg82gwTqgGlD6kQw6gSOg
• Facebookfacebook.com/SMTPL
• LinkedInlinkedin.com/company/sahajanand-medical-technologies-pvt-ltd

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries15 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sahajanand Medical Technologies